Nafamostat Mesylate
Sponsors
Gyeongsang National University Hospital, Ensysce Biosciences, Xiaobo Yang, MD, Wonju Severance Christian Hospital, Shen Lei
Conditions
AnticoagulationBleedingCOVID-19Corona Virus InfectionCritical IllnessDialysis; ComplicationsPharmacokineticsSepsis
Phase 1
Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)
CompletedNCT05090280
Start: 2021-12-01End: 2023-04-26Updated: 2024-09-24
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RecruitingNCT06500793
Start: 2024-11-24End: 2026-12-31Target: 30Updated: 2026-03-06
Phase 2
Phase 4
Unknown Phase
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study
RecruitingNCT05874674
Start: 2023-12-01End: 2026-12-31Target: 100Updated: 2024-07-30
The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration
Not yet recruitingNCT06994312
Start: 2025-07-01End: 2028-12-01Target: 282Updated: 2025-05-29